LITESPARK-011: Belzutifán + Lenvatinib mejora la supervivencia libre de progresión | ESMO 2026
Dr. Natalia GandurArgentina
- Type
- Expert pick
- Congress
- ESMO 2026
- Published
- Topic
- Genitourinary
More on genitourinary cancers
Assessing the Risk of Incontinence Before Prostate Cancer Treatment 10e2
More is not always better in kidney cancer: LITESPARK-012 at #ESMO26
VOLGA: Durvalumab + Enfortumab Vedotin mejora la supervivencia en cáncer de vejiga | ESMO 2026
PEACE-1: Abiraterona mejora la supervivencia en cáncer de próstata metastásico | ESMO 2026
A new target in kidney cancer: XmAb819 phase 1 results at #ESMO26
Adjuvant pembrolizumab remains the standard for high-risk ccRCC. Final OS Analysis of KEYNOTE 564
-e6d6a8d836.png&w=3840&q=75)
